Ovarian Cancer Prevention, Detection, and Treatment of the Disease and its Recurrence. Molecular Mechanisms and Personalized Medicine Meeting Report

被引:46
|
作者
Modugno, Francesmary [1 ,2 ,3 ,4 ]
Edwards, Robert P. [1 ,3 ,4 ]
机构
[1] Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA
[2] Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA
[3] Magee Womens Res Inst, Womens Canc Res Ctr, Pittsburgh, PA USA
[4] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
关键词
Ovarian neoplasms; Epidemiology; Etiology; Screening; Biomarkers; Proteomics; Genomics; Metabalomics; BRCA1/2; Cancer stem cells; Micro RNA; Nuclear receptors; Individualized medicine; Cancer vaccines; Quality of life; Patient reportable outcomes; Therapeutics; Clinical trials; Survival; WOMEN; RISK;
D O I
10.1097/IGC.0b013e31826bd1f2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To review the current understanding of the underlying molecular, biologic, and genetic mechanisms involved in ovarian cancer development and how these mechanisms can be targets for prevention, detection, and treatment of the disease and its recurrence. Methods: In May 2012, we convened a meeting of researchers, clinicians, and consumer advocates to review the state of current knowledge on molecular mechanisms and identify fruitful areas for further investigations. Results: The meeting consisted of 7 scientific sessions ranging from Epidemiology, Early Detection, and Biology to Therapeutics and Quality of Life. Sessions consisted of talks and panel discussions by international leaders in ovarian cancer research. A special career development session by the Congressionally Directed Medical Research Program Department of Defense Ovarian Cancer Academy as well as an oral abstract and poster session showcased promising new research by junior scientists. Conclusions: Technological advances in the last decade have increased our knowledge of the molecular mechanisms involved in a host of biological activities related to ovarian cancer. Understanding the role these mechanisms play in cancer initiation and progression will help lead to the development of prevention and treatment modalities that can be personalized to each patient, thereby helping to overcome this highly fatal malignancy.
引用
收藏
页码:S45 / S57
页数:13
相关论文
共 10 条
  • [1] MicroRNA as biomarkers in early detection and personalized treatment in ovarian cancer: Development of a personalized prevention consortium
    Fortner, Renee Turzanski
    langseth, HilDe
    CANCER RESEARCH, 2024, 84 (05)
  • [3] Meeting report from the 2018 12th Biennial Ovarian Cancer Research Symposium detection and prevention of ovarian cancer
    Xian, Wa
    George, Sophia
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : S2 - S6
  • [4] Molecular mechanisms of curcumin and its analogs in colon cancer prevention and treatment
    Selvam, Chelliah
    Prabu, Sakthivel Lakshmana
    Jordan, Brian C.
    Purushothaman, Yasodha
    Umamaheswari, Appavoo
    Zare, Maryam Sadat Hosseini
    Thilagavathi, Ramasamy
    LIFE SCIENCES, 2019, 239
  • [5] Molecular mechanisms of curcumin and its semisynthetic analogues in prostate cancer prevention and treatment
    Jordan, Brian C.
    Mock, Charlotta D.
    Thilagavathi, Ramasamy
    Selvam, Chelliah
    LIFE SCIENCES, 2016, 152 : 135 - 144
  • [6] Circulating tumor DNA-based detection of molecular residual disease as a biomarker for recurrence monitoring predict disease recurrence in patients with ovarian cancer.
    Lv, Tianjiao
    Shi, Xinyi
    Zhao, Dan
    Sun, Jing
    Wang, Bo
    Lu, Kai
    Zou, ShiPing
    Wang, Jing
    Wang, Qiang
    Feng, Weiwei
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] Genomics in personalized cancer medicine and its impact on earlydrug development in China: report from the 6th Annual Meeting of the US Chinese Anti-Cancer Association(USCACA) at the 50th ASCOAnnual Meeting
    Wei Zhang
    ShiYuan Cheng
    LiFang Hou
    Li Yan
    YunGuang Tong
    Chinese Journal of Cancer, 2014, 33 (08) : 371 - 375
  • [8] Genomics in personalized cancer medicine and its impact on early drug development in China: report from the 6th Annual Meeting of the US Chinese Anti-Cancer Association (USCACA) at the 50th ASCO Annual Meeting
    Zhang, Wei
    Cheng, Shi-Yuan
    Hou, Li-Fang
    Yan, Li
    Tong, Yun-Guang
    CHINESE JOURNAL OF CANCER, 2014, 33 (08) : 371 - 375
  • [9] Treatment monitoring utilizing ctDNA-based molecular residual disease detection in patients with recurrent endometrial cancer and recurrent platinum-resistant ovarian cancer
    Backes, Floor
    Cosgrove, Casey
    Scalise, Carly Bess
    Chambers, Laura
    Nagel, Christa
    Bixel, Kristin
    Copeland, Larry
    Wei, Lai
    Myerscough, Callan
    Herman, Molly
    Sours, Emma
    Hays, John
    Kalashnikova, Ekaterina
    Hook, Nicole
    Dutta, Punashi
    Cohn, David
    Liu, Minetta
    ElNaggar, Adam
    O'Malley, David
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S228 - S229
  • [10] Prevention of disease progression in a patient with a gastric cancer-re-recurrence. Outcome after intravenous treatment with the novel antineoplastic agent taurolidine. Report of a case
    Braumann C.
    Winkler G.L.
    Rogalla P.
    Menenakos C.
    Jacobi C.A.
    World Journal of Surgical Oncology, 4 (1)